When can treatment of hypertension be stopped? Michael A. Weber Clinical Trials Report Pages: 279 - 280
Statins and blood pressure regulation Claudio BorghiMaddalena VeronesiEttore Ambrosioni OriginalPaper Pages: 281 - 288
The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection? Michael C. Ruddy OriginalPaper Pages: 289 - 296
The effect of antihypertensive drugs on vascular compliance Nathaniel WinerMichael A. WeberJames R. Sowers OriginalPaper Pages: 297 - 304
Do most antihypertensive agents have a sympatholytic action? Jacques de Champlain OriginalPaper Pages: 305 - 313
Central sympathoinhibitory effects of calcium channel blockers Frans H. H. LeenenMarcel RuzickaBing S. Huang OriginalPaper Pages: 314 - 321
The therapeutic potential of endothelin receptor antagonists in cardiovascular disease Matthias BartonWolfgang Kiowski OriginalPaper Pages: 322 - 330
The benefit of treating isolated systolic hypertension Ji-Guang WangJan A. Staessen OriginalPaper Pages: 333 - 339
Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes Neil ChapmanBruce Neal OriginalPaper Pages: 340 - 349
The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing Alberto Zanchetti OriginalPaper Pages: 350 - 359
Lessons learned from prematurely terminated clinical trials Domenic Sica OriginalPaper Pages: 360 - 366
